tirzepatide cv outcomes π In a large real-world study, was associated with a lower incidence of major cardiovascular vs semaglutide: π Composite outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) β€οΈ New-onset heart UC Irvine researchers project cardiac
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 6 - Aug 11



























